

Attorney Docket No.: RTS-0339
Inventors: Kenneth W. Dobie
Serial No.: 10/024,396
Filing Date: December 18, 2001
Page 2

This listing of claims will replace all prior versions and listings of claims in the application:

Listing of the Claims:

Claim 1 (currently amended): A compound 8 to 50 nucleobases in length targeted to nucleobases 19 through 38 of a 5'-untranslated region, nucleobases 62 through 88 of a start codon region, nucleobases 169 through 1594 of a coding region, nucleobases 1588 through 1607 of a stop codon region, or nucleobases 1792 through 2537 of a 3'-untranslated region of a nucleic acid molecule encoding CD36L1 of SEQ ID NO: 3, wherein said compound specifically hybridizes with one of said regions and inhibits the expression of CD36L1.

Claim 2 (original): The compound of claim 1 which is an antisense oligonucleotide.

Claim 3 (previously canceled).

Claim 4 (original): The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified internucleoside linkage.

Claim 5 (original): The compound of claim 4 wherein the modified internucleoside linkage is a phosphorothioate linkage.


Attorney Docket No.: **RTS-0339**
Inventors: **Kenneth W. Dobie**
Serial No.: **10/024,396**
Filing Date: **December 18, 2001**
Page 3

Claim 6 (original): The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified sugar moiety.

Claim 7 (original): The compound of claim 6 wherein the modified sugar moiety is a 2'-o-methoxyethyl sugar moiety.

Claim 8 (original): The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified nucleobase.

Claim 9 (original): The compound of claim 8 wherein the modified nucleobase is a 5-methylcytosine.

 Claim 10 (original): The compound of claim 2 wherein the antisense oligonucleotide is a chimeric oligonucleotide.

Claim 11 (previously canceled).


Claim 12 (original): A composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier or diluent.

Claim 13 (original): The composition of claim 12 further comprising a colloidal dispersion system.

Claim 14 (original): The composition of claim 12 wherein the compound is an antisense oligonucleotide.

Claim 15 (previously amended): A method of inhibiting the expression of CD36L1 in cells or tissues comprising contacting said

Attorney Docket No.: **RTS-0339**
Inventors: **Kenneth W. Dobie**
Serial No.: **10/024,396**
Filing Date: **December 18, 2001**
Page 4

 cells or tissues in vitro with the compound of claim 1 so that expression of CD36L1 is inhibited.

Claims 16-20 (previously canceled).
